NUVB

Nuvation BioA

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$17.00

+271.2% vs current

Most likely

Base case

60%

Probability

Target price

$9.85

+115.1% vs current

B-

Bear case

20%

Probability

Target price

$5.00

+9.2% vs current

AI sentiment snapshot

Latest data as of 2026-01-20

AI commentary

Analyst median and high materially exceed the anchor, indicating upside potential but with wide dispersion (low-to-high spread). Near-term sentiment is cautious—binary readouts and financing risk dominate headlines and will likely drive volatility [#SERP-2][#SERP-5].

RankAlpha Sentiment AI - 2026-01-20

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-20catalystNear-term clinical data readout (assumed)High impact

Potential near-term clinical readout for an ongoing program; no public date disclosed so a conservative 90-day estimate is used for short-horizon planning [#SERP-2].

2027-01-20catalystPipeline advancement / commercialization optionalityHigh impact

Longer-term value from positive pivotal/partnering outcomes or commercialization milestones; modeled on a 12-month+ horizon consistent with analyst 12-month framing [#SERP-5].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-20 • Updated nightlySource: Internal modelMethodology